Skip to content
2000
image of Comprehending the Potential of Topical Therapies for the Treatment of Onychomycosis

Abstract

Introduction

Onychomycosis is a frequently occurring fungal infection that affects the nails of the fingers and toes. Infection is caused by yeasts, dermatophytes, and nondermatophyte molds. Onychomycosis should be confirmed by mycology. Diagnosis can be made by various techniques, such as microscopy, fungal culture, potassium hydroxide, polymerase chain reaction, and histopathology. This review was undertaken to study the challenges associated with topical therapy of onychomycosis and techniques to overcome these challenges.

Methods

The search engines used for carrying out the literature review were PubMed, Google, Scopus, and Google Scholar. The search terms employed were “topical therapies for onychomycosis”, “diagnosis of onychomycosis”, and “challenges in the treatment of onychomycosis”. The data related to topical treatments were compiled, and articles available in English language were only considered.

Results and Discussion

The main challenge associated with topical therapy was found to be the unique structure of the nails, hampering drug penetration to the infection site and inducing fungal drug resistance. Conventional treatment methods, as well as novel techniques developed for topical therapy, like microporation, ionotophoresis, laser, and photodynamic therapy, have also been explored. Oral antifungals are most commonly used for moderate to severe onychomycosis as they provide greater cure rates, whereas topical application of antifungals is advocated for mild to moderate infections as it possesses a better safety profile. Efinaconazole solution (10%), tavaborole solution (5%), and ciclopirox nail lacquer (8%) for topical use are accepted by the Food and Drug Administration (FDA) for the management of onychomycosis. Laser treatment is approved in the United States for the short-term improvement of clear nails in fungal infections, but the clinical outcomes have not yet reached optimal levels.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/raddf/10.2174/0126673878340909250628080713
2025-07-14
2025-09-28

  • From This Site

    /content/journals/raddf/10.2174/0126673878340909250628080713
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Angelo T. Borgheti-Cardoso L.N. Gelfuso G.M. Taveira S.F. Gratieri T. Chemical and physical strategies in onychomycosis topical treatment: A review. Med. Mycol. 2017 55 5 461 475 27703019
    [Google Scholar]
  2. Gregoriou S. Kyriazopoulou M. Tsiogka A. Rigopoulos D. Novel and investigational treatments for onychomycosis. J. Fungi 2022 8 10 1079 10.3390/jof8101079 36294644
    [Google Scholar]
  3. Hay R. Therapy of skin, hair and nail fungal infections. J. Fungi 2018 4 3 99 10.3390/jof4030099 30127244
    [Google Scholar]
  4. Sujata K. Gitanjali C. Naresh J. Formulation and evaluation of antifungal drug terbinafine hydrochloride for the treatment of athlete’s foot. Int J Pharm Res Appl 2022 7 2152 2153
    [Google Scholar]
  5. Piraccini B. Alessandrini A. Onychomycosis: A review. J. Fungi 2015 1 1 30 43 10.3390/jof1010030 29376897
    [Google Scholar]
  6. Akhtar N. Sharma H. Pathak K. Onychomycosis: Potential of nail lacquers in transungual delivery of antifungals. Scientifica 2016 2016 1 12 10.1155/2016/1387936 27123362
    [Google Scholar]
  7. Roberts D.T. Taylor W.D. Boyle J. Guidelines for treatment of onychomycosis. Br. J. Dermatol. 2003 148 3 402 410 10.1046/j.1365‑2133.2003.05242.x 12653730
    [Google Scholar]
  8. Falotico J.M. Lipner S.R. Updated perspectives on the diagnosis and management of onychomycosis. Clin. Cosmet. Investig. Dermatol. 2022 15 1933 1957 10.2147/CCID.S362635 36133401
    [Google Scholar]
  9. Walters K.A. Abdalghafor H.M. Lane M.E. The human nail – Barrier characterisation and permeation enhancement. Int. J. Pharm. 2012 435 1 10 21 10.1016/j.ijpharm.2012.04.024 22521879
    [Google Scholar]
  10. Lipner S.R. Scher R.K. Onychomycosis. J. Am. Acad. Dermatol. 2019 80 4 853 867 10.1016/j.jaad.2018.05.1260 29959962
    [Google Scholar]
  11. Ishack S. Miller R.C. Lipner S.R. Regarding terbinafine associated hepatotoxicity in an assessment of online information. J. Am. Acad. Dermatol. 2022 86 6 269 271 10.1016/j.jaad.2022.02.006 35150758
    [Google Scholar]
  12. Aran R. Dawber R.P.R. Tosti A. Haneke E. Onychomycosis and its treatment. A Text Atlas of Nail Disorders Diagnosis and Treatment. London CRC Press 1996
    [Google Scholar]
  13. Hay R.J. Baran R. Moore M.K. Wilkinson J.D. Candida onychomycosis—an evaluation of the role of Candida species in nail disease. Br. J. Dermatol. 1988 118 1 47 58 10.1111/j.1365‑2133.1988.tb01749.x 3342176
    [Google Scholar]
  14. Weismann K. Knudsen E.A. Pedersen C. White nails in AIDS/ARC due to Trichophyton rubrum infection. Clin. Exp. Dermatol. 1988 13 1 24 25 10.1111/j.1365‑2230.1988.tb00643.x 2974764
    [Google Scholar]
  15. Kalter D.C. Hay R.J. Onychomycosis due to Trichophyton soudanense. Clin. Exp. Dermatol. 1988 13 4 221 227 10.1111/j.1365‑2230.1988.tb00683.x 2977577
    [Google Scholar]
  16. Hay R.J. Baran R. Fungal (onychomycosis) and other infections of the nail apparatus. Diseases of the Nails and Their Management. Baran R. Dawber R.P.R. Oxford Blackwell Scientific Publications 1984 121 155
    [Google Scholar]
  17. Vejnovic I. Simmler L. Betz G. Investigation of different formulations for drug delivery through the nail plate. Int. J. Pharm. 2010 386 1-2 185 194 10.1016/j.ijpharm.2009.11.019 19941943
    [Google Scholar]
  18. Gupta A.K. Uro M. Cooper E.A. Onychomycosis therapy: Past, present, future. J. Drugs Dermatol. 2010 9 9 1109 1113 20865843
    [Google Scholar]
  19. Foley K. Gupta A.K. Versteeg S. Mays R. Villanueva E. John D. Topical and device-based treatments for fungal infections of the toenails. Cochrane Libr. 2020 1 1 CD012093 10.1002/14651858.CD012093.pub2 31978269
    [Google Scholar]
  20. Lipner S.R. Ko D. Optimizing topical therapy for onychomycosis: The importance of patient education. Importance of Patient Education 2018 102 6 389 390 30657804
    [Google Scholar]
  21. Boni E. Elewski M.D. Efinaconazole 10% solution in the treatment of Toenail Onychomycosis. J. Am. Acad. Dermatol. 2013 68 4 600 605 23177180
    [Google Scholar]
  22. Elewski B.E. Aly R. Baldwin S.L. Efficacy and safety of tavaborole topical solution, 5%, a novel boron-based antifungal agent, for the treatment of toenail onychomycosis: Results from 2 randomized phase-III studies. J. Am. Acad. Dermatol. 2015 73 1 62 69 10.1016/j.jaad.2015.04.010 25956661
    [Google Scholar]
  23. Lauharanta J. Comparative efficacy and safety of amorolfine nail lacquer 2% versus 5% once weekly. Clin Exp Dermatol 1992 17 s1 41 43.(Suppl. 1) 10.1111/j.1365‑2230.1992.tb00277.x 1458664
    [Google Scholar]
  24. Gupta A.K. Paquet M. A retrospective chart review of the clinical efficacy of Nd:YAG 1064-nm laser for toenail onychomycosis. J. Dermatolog. Treat. 2015 26 4 376 378 10.3109/09546634.2014.975671 25329992
    [Google Scholar]
  25. Souza L.W.F. Souza S.V.T. Botelho A.C.C. Distal and lateral toenail onychomycosis caused by Trichophyton rubrum: Treatment with photodynamic therapy based on methylene blue dye. An. Bras. Dermatol. 2014 89 1 184 186 10.1590/abd1806‑4841.20142197 24626676
    [Google Scholar]
  26. Sais G. Jugglág A. Peyrí J. Prevalence of dermatophyte onychomycosis in Spain: A cross-sectional study. Br. J. Dermatol. 1995 132 5 758 761 10.1111/j.1365‑2133.1995.tb00722.x 7772481
    [Google Scholar]
  27. Zaug M. Bergstraesser M. Amorolfine in onychomycosis and dermatomycosis. Clin. Exp. Dermatol. 1992 17 61 65 10.1111/j.1365‑2230.1992.tb00281.x 1458669
    [Google Scholar]
  28. Baran R. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis. Br J Dermatol 2001 145 S60 15 19.(Suppl. 60) 10.1046/j.1365‑2133.2001.00045.x 11777260
    [Google Scholar]
  29. Rajendra V.B. Baro A. Kumari A. Dhamecha D.L. Lahoti S.R. Shelke S.D. Transungual drug delivery: An overview. J. Appl. Pharm. Sci. 2012 2 1 203 207
    [Google Scholar]
  30. Hui X. Wester R.C. Barbadillo S. Ciclopirox delivery into the human nail plate. J. Pharm. Sci. 2004 93 10 2545 2548 10.1002/jps.20159 15349963
    [Google Scholar]
  31. Kim Y.J. Han S.S. Yang H.J. Chang S.E. Prospective, comparative evaluation of a deep neural network and dermoscopy in the diagnosis of onychomycosis. PLoS One 2020 15 6 e0234334 10.1371/journal.pone.0234334
    [Google Scholar]
  32. de Berker D. Management of psoriatic nail disease. J. Pharm. Sci. 2009 28 1 39 43 19341941
    [Google Scholar]
  33. Smith K.A. Hao J. Kevin Li S. Effects of organic solvents on the barrier properties of human nail. J. Pharm. Sci. 2011 100 10 4244 4257 10.1002/jps.22590 21607952
    [Google Scholar]
  34. Basini P.N. Kr D.B. Nail drug delivery syatem: A review. J. Adv. Pharm. Educ. Res. 2012 2 3 101 107
    [Google Scholar]
  35. Scher R Rich P Elewski B Pariser D The epidemiology, etiology, and pathophysiology of onychomycosis. Semin Cutan Med Surg 2013 32 2S S2 4.(Suppl. 1) 10.12788/j.sder.0014 24156160
    [Google Scholar]
  36. Hay R.J. Mackie R.M. Clayton Y.M. Tioconazole nail solution-an open study of its efficacy in onychomycosis. Clin. Exp. Dermatol. 1985 10 2 111 115 10.1111/j.1365‑2230.1985.tb00537.x 3156698
    [Google Scholar]
  37. WHO guidelines on the treatment of skin and oral HIV-associated conditions in children and adults. 2014 Available from: http://www.who.int/maternal_child_adolescent/document/skin-mucosa-and-hiv/en/
  38. Elewski B.E. Onychomycosis: Pathogenesis, diagnosis, and management. Clin. Microbiol. Rev. 1998 11 3 415 429 10.1128/CMR.11.3.415
    [Google Scholar]
  39. Gupta A.K. Paquet M. Simpson F.C. Therapies for the treatment of onychomycosis. Clin. Dermatol. 2013 31 5 544 554 10.1016/j.clindermatol.2013.06.011 24079583
    [Google Scholar]
  40. El-Tatawy R.A. Abd El-Naby N.M. El-Hawary E.E. Talaat R.A.Z. A comparative clinical and mycological study of Nd-YAG laser versus topical terbinafine in the treatment of onychomycosis. J. Dermatolog. Treat. 2015 26 5 461 464 10.3109/09546634.2014.998607 25669435
    [Google Scholar]
  41. Lima E. Reis L.V. History of photodynamic therapy in dermatology. Elsevier Science B 2001 2 3 7
    [Google Scholar]
  42. Baltazar L.M. Ray A. Santos D.A. Cisalpino P.S. Friedman A.J. Nosanchuk J.D. Antimicrobial photodynamic therapy: An effective alternative approach to control fungal infections. Front. Microbiol. 2015 6 202 10.3389/fmicb.2015.00202 25821448
    [Google Scholar]
  43. Gurzadyan G.G. Görner H. Schulte-Frohlinde D. Gorner H. Ultraviolet (193, 216 and 254 nm) photoinactivation of Escherichia coli strains with different repair deficiencies. Radiat. Res. 1995 141 3 244 251 10.2307/3579001 7871151
    [Google Scholar]
  44. Perrin C. Nail anatomy, nail psoriasis, and nail extensor enthesitis theory: What is the link? Am. J. Dermatopathol. 2019 41 6 399 409 10.1097/DAD.0000000000001244 31107704
    [Google Scholar]
  45. Rajendra V.B. Baro A. Kumari A. Dhamecha D.L. Lahoti S.R. Shelke S.D. Transungual drug delivery: An overview. J. Pharm. Sci. 2012 2 1 203 204
    [Google Scholar]
  46. Haneke E. Anatomy of the nail unit and the nail biopsy. Semin. Cutan. Med. Surg. 2015 34 2 95 100 10.12788/j.sder.2015.0143
    [Google Scholar]
  47. Onychomycosis: Potential of nail lacquers in transungual delivery of antifungals. Available from: https://www.researchgate.net/
  48. de Berker D. Nail anatomy. Clin. Dermatol. 2013 31 5 509 515 10.1016/j.clindermatol.2013.06.006 24079579
    [Google Scholar]
  49. Saeedi P. Shavandi A. Meredith-Jones K. Nail properties and bone health: A review. J. Funct. Biomater. 2018 9 2 31 10.3390/jfb9020031 29690604
    [Google Scholar]
  50. Gratieri T. Krawczyk-Santos A.P. da Rocha P.B.R. SLN- and NLC-encapsulating antifungal agents: Skin drug delivery and their unexplored potential for treating onychomycosis. Curr. Pharm. Des. 2018 23 43 6684 6695 10.2174/1381612823666171115112745 29141535
    [Google Scholar]
  51. Nafisi S. Maibach H.I. Skin penetration of nanoparticles. Emerging Nanotechnologies in Immunology. Elsevier 2018 47 82 10.1016/B978‑0‑323‑40016‑9.00003‑8
    [Google Scholar]
  52. Pattanaik S. Topical drug delivery of antimicrobial agent using modern technique to treat various nail infection. Pensee 2021 51 1 708 721
    [Google Scholar]
  53. Gupta A.K. Cooper E.A. Update in antifungal therapy of dermatophytosis. Mycopathologia 2008 166 5-6 353 367 10.1007/s11046‑008‑9109‑0 18478357
    [Google Scholar]
  54. Vlahovic T.C. Onychomycosis. Clin. Podiatr. Med. Surg. 2016 33 3 305 318 10.1016/j.cpm.2016.02.001 27215153
    [Google Scholar]
  55. Vasconcellos C. Pereira C.Q.M. Souza M.C. Pelegrini A. Freitas R.S. Takahashi J.P. Identification of fungi species in the onychomycosis of institutionalized elderly. An. Bras. Dermatol. 2013 88 3 377 380 10.1590/abd1806‑4841.20131884 23793195
    [Google Scholar]
  56. Gupta A.K. Gupta G. Jain H.C. The prevalence of unsuspected onychomycosis and its causative organisms in a multicentre Canadian sample of 30 000 patients visiting physicians’ offices. J. Eur. Acad. Dermatol. Venereol. 2016 30 9 1567 1572 10.1111/jdv.13677 27168494
    [Google Scholar]
  57. Hamishehkar H. Rahimpour Y. Kouhsoltani M. Niosomes as a propitious carrier for topical drug delivery. Expert Opin. Drug Deliv. 2013 10 2 261 272 10.1517/17425247.2013.746310 23252629
    [Google Scholar]
  58. El-Ridy M.S. Abdelbary A. Essam T. Abd EL-Salam RM, Aly Kassem AA. Niosomes as a potential drug delivery system for increasing the efficacy and safety of nystatin. Drug Dev. Ind. Pharm. 2011 37 12 1491 1508 10.3109/03639045.2011.587431 21707323
    [Google Scholar]
  59. Shear N.H. Villars V.V. Marsolais C. Terbinafine: An oral and topical antifungal agent. Clin. Dermatol. 1991 9 4 487 495 10.1016/0738‑081X(91)90077‑X 1840406
    [Google Scholar]
  60. Elewski B.E. Hay R.J. Update on the management of onychomycosis: Highlights of the third annual international summit on cutaneous antifungal therapy. Clin. Infect. Dis. 1996 23 2 305 313 10.1093/clinids/23.2.305 8842269
    [Google Scholar]
  61. Hasim S. Coleman J.J. Targeting the fungal cell wall: Current therapies and implications for development of alternative antifungal agents. Future Med. Chem. 2019 11 8 869 883 10.4155/fmc‑2018‑0465 30994368
    [Google Scholar]
  62. Rayens E. Norris K.A. Prevalence and healthcare burden of fungal infections in the United States, 2018. Open Forum Infect. Dis. 2022 9 1 ofab593 10.1093/ofid/ofab593 35036461
    [Google Scholar]
  63. Bouz G. Doležal M. Advances in antifungal drug development: An up-to-date mini review. Pharmaceuticals 2021 14 12 1312 10.3390/ph14121312 34959712
    [Google Scholar]
  64. Heikkilå H. Stubb S. The prevalence of onychomycosis in Finland. Br. J. Dermatol. 1995 133 5 699 703 10.1111/j.1365‑2133.1995.tb02741.x 8555019
    [Google Scholar]
  65. Degreef H. De Doncker P. Fighting fungal infections around the globe. Itraconazole in Perspective. Kent Wells Medical Holdings 2000 57 61
    [Google Scholar]
  66. Bolognia J.L. Jorizzo J.L. Rapini R.P. Dermatology. New York Mosby 2003 1176 1178
    [Google Scholar]
  67. Gabard B. Elsner P. Surber C. Treffel P. Dermatopharmacology of Topical Preparations: A Product-Development Oriented Approach. Berlin Springer-Verlag 2000 255 280 10.1007/978‑3‑642‑57145‑9
    [Google Scholar]
  68. Kasting G.B. Barai N.D. Equilibrium water sorption in human stratum corneum. J. Pharm. Sci. 2003 92 8 1624 1631 10.1002/jps.10420 12884249
    [Google Scholar]
  69. Naik A. Kalia Y.N. Guy R.H. Transdermal drug delivery: Overcoming the skin’s barrier function. Pharm. Sci. Technol. Today 2000 3 9 318 326 10.1016/S1461‑5347(00)00295‑9 10996573
    [Google Scholar]
  70. Garber G. An overview of fungal infections. 2001
    [Google Scholar]
  71. Hanifin J.M. Cooper K.D. Ho V.C. Guidelines of care for atopic dermatitis. J. Am. Acad. Dermatol. 2004 50 3 391 404 10.1016/j.jaad.2003.08.003 14988682
    [Google Scholar]
  72. Elewski B Pariser D Rich P Scher R Current and emerging options in the treatment of onychomycosis. 2013
    [Google Scholar]
  73. Sudaxshina M. Enhancing the nail permeability of topically applied drugs. Expert Opin. Drug Deliv. 2008 5 11 1267 1282 10.1517/17425240802497218
    [Google Scholar]
  74. Axler E. Antifungal selection for the treatment of onychomycosis: Patient considerations and outcomes. Infect. Drug Resist. 2024 17 819 843 10.2147/IDR.S431526
    [Google Scholar]
  75. Konin J.G. Saliba S. Borsa P. Light amplification by stimulated emission of radiation. Athl. Train. Sports Health Care 2009 1 6 253 255 10.3928/19425864‑20091020‑02
    [Google Scholar]
  76. Henderson T.A. Near-infrared photonic energy penetration: can infrared phototherapy effectively reach the human brain? Neuropsychiatr. Dis. Treat. 2015 11 2191 2208 10.2147/NDT.S78182
    [Google Scholar]
  77. Mussttaf R.A. Jenkins D.F.L. Jha A.N. Assessing the impact of low level laser therapy (LLLT) on biological systems: A review. Int. J. Radiat. Biol. 2019 95 2 120 143 10.1080/09553002.2019.1524944 30614743
    [Google Scholar]
  78. Dixit N. Bali V. Baboota S. Ahuja A. Ali J. Iontophoresis - An approach for controlled drug delivery: A review. Curr. Drug Deliv. 2007 4 1 1 10 17269912
    [Google Scholar]
  79. Sugarman J.L. Parish L.C. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J. Drugs Dermatol. 2009 8 12 1106 1111 20027938
    [Google Scholar]
  80. Foldvari M. Non-invasive administration of drugs through the skin: Challenges in delivery system design. Pharm. Sci. Technol. Today 2000 3 12 417 425 10.1016/S1461‑5347(00)00317‑5 11116201
    [Google Scholar]
  81. Jain N.K. Advances in Controlled and Novel Drug Delivery. 1st ed New Delhi CBS Publishers and Distributors 2001 426 451
    [Google Scholar]
  82. Sudaxshina M. Murdan S. Drug delivery to the nail following topical application. Int. J. Pharm. 2010 392 1–2 314
    [Google Scholar]
  83. Ritupama C. Fungal Infection: An Unrecognized Threat. Academic Press 2023 625 644
    [Google Scholar]
  84. Gupta A.K. Versteeg S.G. Shear N.H. Onychomycosis in the 21st century: An update on diagnosis, epidemiology, and treatment. J. Cutan. Med. Surg. 2017 21 6 525 539 10.1177/1203475417716362 28639462
    [Google Scholar]
  85. 2008
  86. Gräser Y. Scott J. Summerbell R. The new species concept in dermatophytes-a polyphasic approach. Mycopathologia 2008 166 5-6 239 256 10.1007/s11046‑008‑9099‑y 18478366
    [Google Scholar]
  87. Del Rosso J.Q. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J. Clin. Aesthet. Dermatol. 2014 7 7 10 18 25053979
    [Google Scholar]
  88. Gupta A.K. Ryder J.E. Skinner A.R. Treatment of onychomycosis: Pros and cons of antifungal agents. J. Cutan. Med. Surg. 2004 8 1 25 30 10.1177/120347540400800107 15688097
    [Google Scholar]
  89. de Sá D.C. Lamas A.P.B. Tosti A. Oral therapy for onychomycosis: An evidence-based review. Am. J. Clin. Dermatol. 2014 15 1 17 36 10.1007/s40257‑013‑0056‑2 24352873
    [Google Scholar]
  90. Basini P.N. Kr D.B. Nail drug delivery system: A review. J. Adv. Pharm. Educ. Res. 2012 2 3 101 109
    [Google Scholar]
  91. Vikas A. Rashmin P. Mrunali P. Chavan R.B. Kaushik T. Mechanistic insights of formulation approaches for the treatment of nail infection: Conventional and novel drug delivery approaches. AAPS PharmSciTech 2020 21 2 67 10.1208/s12249‑019‑1591‑9 31938980
    [Google Scholar]
  92. Keneth A. Drug penetration enhancement through human nail and skin. 2007
    [Google Scholar]
  93. Aggarwal R. Targhotra M. Kumar B. Sahoo P.K. Chauhan M.K. Treatment and management strategies of onychomycosis. J. Mycol. Med. 2020 30 2 100949 10.1016/j.mycmed.2020.100949 32234349
    [Google Scholar]
  94. Abd-Elsalam W.H. Abouelatta S.M. Contemporary techniques and potential transungual drug delivery nanosystems for the treatment of onychomycosis. AAPS PharmSciTech 2023 24 6 150 10.1208/s12249‑023‑02603‑x 37421509
    [Google Scholar]
  95. Kumar Behera J. Kumar S. Sharma R. Novel discoveries and clinical advancements for treating onychomycosis: A mechanistic insight. Adv. Drug Deliv. Rev. 2024 205 115174 10.1016/j.addr.2023.115174 38161056
    [Google Scholar]
  96. Debruyne D. Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin. Pharmacokinet. 2001 40 6 441 472 10.2165/00003088‑200140060‑00005 11475469
    [Google Scholar]
  97. Zane L.T. Chanda S. Coronado D. Del Rosso J. Antifungal agents for onychomycosis: New treatment strategies to improve safety. Dermatol. Online J. 2016 22 3 1 12 10.5070/D3223030383 27136621
    [Google Scholar]
  98. Giri Y. Behera A. Mohanty B. Pattnaik G. Habibullah S.K. Transungual drug delivery system for the topical treatment of onychomycosis: A review. Drug Deliv. Lett. 2022 12 1 2 18 10.2174/2210303112666220224110100
    [Google Scholar]
  99. Verma S. An emanation of nail lacquer in the management of nail disorders: A comprehensive review. World J. Pharm. Res. 2020 10 1 870 898
    [Google Scholar]
  100. Subissi A. Monti D. Togni G. Mailland F. Ciclopirox. Drugs 2010 70 16 2133 2152 10.2165/11538110‑000000000‑00000 20964457
    [Google Scholar]
  101. Markinson B. Caldwell B. Efinaconazole topical solution, 10%. J. Am. Podiatr. Med. Assoc. 2015 105 5 407 411 10.7547/14‑088 26429609
    [Google Scholar]
  102. Ricardo J.W. Lipner S.R. Safety of current therapies for onychomycosis. Expert Opin. Drug Saf. 2020 19 11 1395 1408 10.1080/14740338.2020.1829592 32990062
    [Google Scholar]
  103. Sigurgeirsson B. Hay R.J. The antifungal drugs used in skin disease. Antibiot Antifung Ther Dermatol 2016 4 141 156 10.1007/978‑3‑319‑39424‑4_7
    [Google Scholar]
  104. Kayla M. Tavaborale, efinaconazole, luliconazole: Three new antimycotic agents for the treatment of dermatophytic fungi. J. Pharm. Pract. 2016 30 6 1
    [Google Scholar]
  105. Nematollahi A.R. Badiee P. Nournia E. The efficacy of ultraviolet irradiation on trichophyton species isolated from nails. Jundishapur J. Microbiol. 2015 8 6 e18158 10.5812/jjm.18158v2 26322201
    [Google Scholar]
/content/journals/raddf/10.2174/0126673878340909250628080713
Loading
Comprehending the Potential of Topical Therapies for the Treatment of Onychomycosis
Bentham Science Publishers ; https://doi.org/10.2174/0126673878340909250628080713
/content/journals/raddf/10.2174/0126673878340909250628080713
/content/journals/raddf/10.2174/0126673878340909250628080713
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: nails ; Onychomycosis ; topical therapy ; antifungals ; fungal infection ; diagnosis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test